2587:TSESuntory Beverage & Food Ltd. Analysis

The stock trades at HK$5.14, well above the DCF fair value of about HK$1.05, indicating a significant overvaluation. Technicals show the 20‑day SMA (5.11) sitting just above the current price while the 200‑day SMA (10.60) remains far higher, signaling a long‑term downtrend. RSI at 53 suggests neutral momentum, and the MACD histogram is negative with a bearish signal line, confirming short‑term weakness. Volume is on a decreasing trend, and the 30‑day volatility spikes above 75%, reflecting unstable price swings. Beta is low at 0.26, which tempers market‑wide moves but does not offset company‑specific risk.
Fundamentally, HealthyWay posted a 15% revenue decline and a negative profit margin of –18.6%, with trailing EPS of –0.27 and no dividend. The price‑to‑book ratio of 16.9 is far above typical industry levels, and free cash flow is deeply negative, highlighting cash‑burn concerns. The max drawdown of –92% underscores the stock’s historical fragility. Combined with high regulatory scrutiny in China’s health‑information sector, these factors point to a cautious stance. Investors should therefore treat the stock as overvalued and prioritize risk mitigation.